[go: up one dir, main page]

WO2006119598A3 - Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor - Google Patents

Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor Download PDF

Info

Publication number
WO2006119598A3
WO2006119598A3 PCT/BR2006/000090 BR2006000090W WO2006119598A3 WO 2006119598 A3 WO2006119598 A3 WO 2006119598A3 BR 2006000090 W BR2006000090 W BR 2006000090W WO 2006119598 A3 WO2006119598 A3 WO 2006119598A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
optionally
combination
fatty acid
coa reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2006/000090
Other languages
French (fr)
Other versions
WO2006119598A2 (en
Inventor
Jean Marc Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2006119598A2 publication Critical patent/WO2006119598A2/en
Publication of WO2006119598A3 publication Critical patent/WO2006119598A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Device for slow liberation via transdermal process of a medicine for reducing an excess of cholesterol and method of production of a transdermic device, which is characterized by a bi-laminate device comprising a flexible macromolecular matrix (2) providing a thickness from 0,15 to 0,6 cm and a surface from 10 to 100 square cm and a posterior coating (1) on one side which allows a considerable reduction (more than 15 times) of the doses to be administered in the treatment of an excess of cholesterol; the macromolecular matrix contains and liberates in a continuous way for a period between 1 to 4 months from 0,05 to 0,18% per day of its total weight of Omega-3 follyocid and / or statin by its surface in contact with the patient's skin without being necessarily the device to be adhered in a fix and permanent way to his / her skin.
PCT/BR2006/000090 2005-05-10 2006-05-10 Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor Ceased WO2006119598A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0501708 BRPI0501708A (en) 2005-05-10 2005-05-10 transdermal slow-release device for an excess cholesterol drug and method of producing a transdermal device
BRPI0501708-4 2005-05-10

Publications (2)

Publication Number Publication Date
WO2006119598A2 WO2006119598A2 (en) 2006-11-16
WO2006119598A3 true WO2006119598A3 (en) 2007-03-01

Family

ID=37396906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2006/000090 Ceased WO2006119598A2 (en) 2005-05-10 2006-05-10 Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor

Country Status (2)

Country Link
BR (1) BRPI0501708A (en)
WO (1) WO2006119598A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940116B1 (en) * 2008-12-22 2012-07-06 Philippe Perovitch FORMULATION FOR THE ADMINISTRATION OF HYPOLIPEMIC BY ORAL TRANS-MUCOSAL
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325130A1 (en) * 1983-06-29 1985-01-03 Pierre-Richard Nizza Dick PHARMACEUTICAL COMPOSITION FOR APPLICATION TO THE SKIN BASED ON ESSENTIAL FATTY ACIDS AND DEVICE CONTAINING THIS
EP0965340A1 (en) * 1996-12-23 1999-12-22 Nippon Suisan Kaisha, Ltd. Dermatologic preparation
WO2002038196A2 (en) * 2000-11-11 2002-05-16 Beiersdorf Ag Plaster with skincare substances

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325130A1 (en) * 1983-06-29 1985-01-03 Pierre-Richard Nizza Dick PHARMACEUTICAL COMPOSITION FOR APPLICATION TO THE SKIN BASED ON ESSENTIAL FATTY ACIDS AND DEVICE CONTAINING THIS
EP0965340A1 (en) * 1996-12-23 1999-12-22 Nippon Suisan Kaisha, Ltd. Dermatologic preparation
WO2002038196A2 (en) * 2000-11-11 2002-05-16 Beiersdorf Ag Plaster with skincare substances

Also Published As

Publication number Publication date
WO2006119598A2 (en) 2006-11-16
BRPI0501708A (en) 2007-05-02

Similar Documents

Publication Publication Date Title
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2008064192A3 (en) Modified release analgesic suspensions
NZ807894A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
EP3150204A3 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2006020884A3 (en) Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
EP2392364A3 (en) Rapamycin coated expandable devices
WO2005107875A3 (en) Triglycerides, fatty acids, alcohols as cns modulators
AU2003246985A1 (en) Apparatus for skin absorption enhancement and transdermal drug delivery
DE50303201D1 (en) HOT GLAZE TTS FOR THE ADMINISTRATION OF ROTIGOTIN
WO2007098479A3 (en) Localized insulin delivery for bone healing
WO2009026178A3 (en) High concentration local anesthetic formulations
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2008151040A3 (en) Analgesic coated medical product
DE602006020070D1 (en) REDUCTION OF SWALLOWS, A SIDE EFFECTS RELATED TO PIRFENIDON THERAPY
WO2008027203A3 (en) Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
NO20054382L (en) Diarylcycloalkyl derivatives, their preparation and their use as a drug
WO2005115381A3 (en) COMPOSITION CONTAINING POLICOSANOL AND HMG-Co-A REDUCTASE INHIBITOR AND THEIR PHARMACEUTICAL USES
DE50212267D1 (en) TRANSDERMALES THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF CARBOXYL GROUP-CONTAINING, NON-TTEROIDAL ANTIPHLOGISTICS, AND METHOD FOR THE PRODUCTION THEREOF
WO2006004449A3 (en) A combination composition
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2006119598A3 (en) Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06721647

Country of ref document: EP

Kind code of ref document: A2